Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 202189-78-4 | Product Number: B5392
Bilastine
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- 2-[4-[2-[4-[1-(2-Ethoxyethyl)-1H-benzo[d]imidazol-2-yl]piperidin-1-yl]ethyl]phenyl]-2-methylpropanoic Acid
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 250MG |
$93.00
|
1 | 1 | ≥60 |
|
| 1G |
$257.00
|
Contact Us | Contact Us | 17 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | B5392 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__8H__3__7N__3O__3 = 463.62 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| CAS RN | 202189-78-4 |
| Reaxys Registry Number | 13851185 |
| PubChem Substance ID | 354335500 |
| MDL Number | MFCD09837814 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 199.0 to 203.0 °C |
Properties (reference)
| Melting Point | 202 °C |
| Solubility in water | Insoluble |
| Solubility (insoluble in) | Methanol |
GHS
Related Laws:
Transport Information:
| HS Number | 2933.39.4100 |
Application
Bilastine: A Selective Histamine H1 Receptor Antagonist
Bilastine is a selective histamine H1 receptor antagonist. On the other hand, the results of studies on bilastine confirmed the lack of significant antagonism against not only histamine H2 and H3 receptors but also serotonin, bradykinin, leukotriene D4, calcium, muscarinic M3-receptors, α1-adrenoceptors, and β2-adrenoceptors. Furthermore, bilastine do not cause sedation or interact with cytochrome P 450. Therefore, bilastine is used as a second generation H1-antihistamine for the treatment of allergic rhinitis and chronic urticarial. For your reference, [P2382] is a synthetic intermediate of bilastine.(The product is for research purpose only.)
References
- Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist. Receptor selectivity and in vitro antihistaminic activity
- In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist
- Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticarial (a review)
- Histamine and H1-antihistamines: Celebrating a century of progress (a review)
- Application of Analytical Quality by Design concept for bilastine and its degradation impurities determination by hydrophilic interaction liquid chromatographic method
PubMed Literature
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.